Anti-C-MPL antibody and use thereof

Abstract

The present invention relates to a novel anti-C-MPL antibody and a use thereof, and specifically, to an anti-C-MPL antibody having an effect of increasing platelet production and its number through the maturation of megakaryocytes in the bone marrow, and a use thereof. The novel anti-C-MPL antibody (2R13) of the present invention is a polymer material and has a longer half-life than the conventional therapeutic agents, and it has the advantage of low self-antibody production and low immunogenicity as an antibody agent. In addition, it can be used as a therapeutic agent for thrombocytopenia by increasing the platelet level of patients suffering from chronic or complication-induced immune thrombocytopenia.

CPC Classifications